# What This Bill Does

This bill extends a government funding program that helps develop medicines for rare diseases. Right now, the program is set to expire at the end of 2022, but this bill would keep it running through 2027, giving it five more years of authorization to operate.

# Why This Matters

Rare diseases affect relatively small numbers of people—conditions like certain genetic disorders, uncommon cancers, or specialized neurological problems. Because so few people have these diseases, pharmaceutical companies often don't develop treatments for them since they won't make much profit. The government created the "orphan drug" program to solve this problem by offering grants and contracts to help companies develop these medicines anyway. Without this funding support, many people with rare conditions would have no treatment options at all.

# Who Gets Affected

Patients with rare diseases and their families would benefit most directly from this bill. If the program had been allowed to expire, the funding would have dried up, potentially slowing or stopping development of new treatments for uncommon conditions. Researchers and pharmaceutical companies working on these medicines also depend on this program to make their work financially feasible. Essentially, this bill keeps hope alive for millions of Americans living with rare diseases by ensuring the government continues investing in treatments that the free market alone wouldn't support.

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

Bilirakis, Gus M.

 <p>This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.</p>